CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
C4 Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.89+0.13 (+4.52%)
Close on Oct 19, 2026
- Market cap
- $377.71M
- P/E (TTM)
- –
- Dividend yield
- –
C4 Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Market Cap | $355.54M | $197.05M |
| Enterprise Value | $55.14M | $106.56M |
| PS Ratio | 10.15 | 3.93 |
| PB Ratio | 1.44 | 2.14 |
| P/TBV Ratio | 1.44 | 2.46 |
Enterprise value
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 1.57 | 2.69 |
Income (trailing twelve months)
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Revenue | $35.04M | $57.94M |
| Operating Income | -$111.77M | -$21.44M |
| Net Income | -$101.42M | -$22.46M |
| EBITDA | -$110.18M | -$16.91M |
| EPS (Diluted) | -$0.99 | -$0.83 |
Margins
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -319.0% | -44.5% |
| Profit Margin | -289.4% | -39.2% |
| EBITDA Margin | -314.5% | -31.3% |
| FCF Margin | -243.7% | -8.85% |
Returns
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -48.1% | -53.1% |
| Return on Assets (ROA) | -30.9% | -41.0% |
| Return on Capital Employed (ROCE) | -35.9% | -37.8% |
Growth
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 2.33% | 6.01% |
| Revenue Growth (3Y CAGR) | 4.95% | 2.25% |
Balance sheet
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $300.40M | $62.42M |
| Net Cash (Debt) | $300.40M | $15.68M |
| Net Cash Per Share | $2.44 | $0.65 |
| Equity (Book Value) | $247.27M | $48.79M |
| Book Value Per Share | $2.01 | $1.36 |
| Tangible Book Value | $247.27M | $23.06M |
| Working Capital | $214.66M | $75.77M |
Financial position
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 5.45 | 3.30 |
| Quick Ratio | 6.25 | 2.39 |
Cash flow (trailing twelve months)
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$84.87M | -$12.35M |
| Capital Expenditures | -$523.00K | -$1.06M |
| Free Cash Flow | -$85.39M | -$20.28M |
| FCF Per Share | -$0.69 | -$0.41 |
Efficiency
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.11 | 0.38 |
| Revenue Per Employee | $336.91K | $398.96K |
| Profits Per Employee | -$975.15K | -$732.08K |
| Employee Count | 104 | 73 |
Dividends and yields
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -28.5% | -21.2% |
| FCF Yield | -24.0% | -7.64% |
| Buyback Yield | 0.07% | -0.58% |
| Shareholder Yield | 0.07% | 0.00% |
Shares
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 123,025,000 | 59,128,900 |
| Shares Change (YoY) | 58.3% | 11.1% |
| Shares Change (QoQ) | 18.1% | 0.54% |
| Float | 119,622,000 | 48,744,500 |
| Shares Held by Insiders | 2.77% | 11.8% |
| Shares Held by Institutions | 95.6% | 59.4% |
Taxes
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Income Tax | $121.00K | $91.50K |
Scores
| Measure | C4 Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -1.38 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from C4 Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.